Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bull of the Day: InMode (INMD)

Bruker

Edwards Lifesciences

Incyte

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why You Should Keep An Eye On These 5 Leading Health Care Stocks

Nevro

Shockwave Medical

These niche businesses are growing by leaps and bounds.

3 Under-the-Radar Healthcare Stocks to Buy in December

This medical tech stock has soared 250% since its August IPO.

Why InMode Stock Skyrocketed 65% in November

Cutera

Sientra

Aesthetics surgery is a big market, and these three companies are positioned to win from its growth.

3 Aesthetics Stocks to Watch

Amarin Corporation Plc

Arrowhead Pharmaceuticals

InMode, Amarin, and Arrowhead Pharmaceuticals are small-cap healthcare stocks working wonders right now.

3 Top Healthcare Stocks to Buy in November

InMode (INMD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

InMode (INMD) Looks Good: Stock Adds 5.6% in Session

CyberOptics

EverBank Financial

Moderna

Top Ranked Momentum Stocks to Buy for November 8th

Celgene

CONMED

So smart investors are looking to cash in by eyeing key health care stocks.

Why You Should Keep An Eye On These 4 Leading Health Care Stocks

Inspire Medical Systems Inc

Tandem Diabetes Care

Including some of these three top medical-device companies in your portfolio now could be savvy.

3 Fast-Growing Medtech Stocks to Buy

InMode Ltd. (INMD) CEO Moshe Mizrahy on Q3 2019 Results - Earnings Call Transcript

This fast-growing medical device company just reported better-than-expected results.

Here's Why InMode Shares Are Jumping 18.5% Today

Nextcure

I'm highly selective with my early investments, and you should be, too

WeWork IPO was a Failure – These 2 IPO Stocks are Surging

Activision Blizzard

Lattice Semiconductor

Overstock.com

Stocks in e-gaming, blockchain and other momentum areas are among our top charts to watch today.

4 Momentum Stocks to Watch.

Sonos

Twitter

These three technology companies, plus a medical device stock, are showing strong technical momentum. Lattice Semiconductor Corporation LSCC[NGS] – $19.98 gained 53 cents to $19.73 on 1.8 million shares Thursday.

Tech Stocks Among Our Top Four Charts to Watch

Three technology companies, plus a medical-device maker, are showing strong technical momentum.

Three technology stocks to watch include Twitter

Wall Street is increasingly optimistic about this medical device company.

Why InMode Shares Surged 12.9% Today

Canadian Solar

HUYA Inc - ADR

Zynex Inc

These four stocks have strong technical momentum aligning with upbeat earnings.

4 Stocks Breaking Out After Earnings

InMode stock popped for a second day running Thursday after the Paula Abdul-backed medical aesthetics company reported strong revenue growth in the second quarter ended June 30.

Paula Abdul-Backed Medical IPO Jumps For Second Day Running

Presidio

Purple Innovation

Good news from these companies helped them avoid a big market sell-off.

Why Purple Innovation, Presidio, and InMode Jumped Today

Shares jump after the newly public medical-device company reports upbeat earnings.

Why InMode Stock Is Soaring Today

Shares of Inmode (NASDAQ: INMD), which went public last week, traded sharply higher Wednesday morning.

Inmode Shares Pop On First Quarterly Print As A Public Company

InMode Ltd. (NASDAQ: INMD) made its public debut Thursday morning, opening at $13.50 after being priced at $14 per share.

News for Inmode Ltd Stock (INMD)